JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
Esta página ha sido traducida por una máquina. Otras páginas pueden seguir apareciendo en inglés. View in English

Jolkinolide B activa la mitofagia para exhibir actividad contra el cáncer pancreático y aliviar los déficits cognitivos en la enfermedad de Alzheimer

  • 0State Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking University, Beijing 100871, China.
Molecular & Cellular Proteomics : Mcp +

|

27 de agosto de 2025

|

27 de agosto de 2025

Ver abstracta en PubMed

Resumen

Este resumen es generado por máquina.

Jolkinolide B, un compuesto natural, mejora específicamente la mitofagia, el proceso de limpieza de las mitocondrias dañadas. Este descubrimiento ofrece un nuevo tratamiento potencial para enfermedades como el cáncer y el Alzheimer al apuntar a la salud mitocondrial.

Área De La Ciencia

  • La bioquímica
  • Biología celular
  • La neurociencia

Sus Antecedentes

  • La mitofagia disfuncional contribuye a enfermedades como el cáncer y el Alzheimer.
  • El desarrollo de reguladores eficaces de la mitofagia es crucial para el tratamiento de los trastornos mitocondriales.
  • Los medicamentos de unión covalente ofrecen una alta especificidad y un bajo potencial de resistencia.

Objetivo Del Estudio

  • Investigar el jolquinolide B (JB) como nuevo regulador de la mitofagia.
  • Para explorar el potencial terapéutico de JB en modelos de cáncer y enfermedad de Alzheimer.

Principales Métodos

  • Estudios in vitro e in vivo con modelos de ratón con cáncer de páncreas y enfermedad de Alzheimer 5 × FAD.
  • Espectrometría de masas para identificar el objetivo molecular de JB.
  • Evaluación de la inducción de la mitofagia, la función mitocondrial y los déficits cognitivos.

Principales Resultados

  • Jolkinolide B induce específicamente la mitofagia al unirse a la proteína TOM40.
  • JB desencadena la muerte celular autofágica en las células de cáncer de páncreas.
  • JB mejora la disfunción mitocondrial y los déficits cognitivos en los modelos de Alzheimer.
  • JB demuestra toxicidad mínima en los modelos probados.

Conclusiones

  • Jolkinolide B es un potenciador de la mitofagia potente y selectivo.
  • JB muestra una promesa terapéutica para las enfermedades mitocondriales, incluyendo el cáncer y el Alzheimer.
  • Dirigirse a la mitofagia con compuestos como JB representa una nueva estrategia terapéutica.

Palabras clave:

Videos de Conceptos Relacionados

Alzheimer's Disease: Treatment 01:22

260

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview 01:26

666

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Electron Transport Chain: Complex I and II 01:46

15.0K

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

PI3K/mTOR/AKT Signaling Pathway 01:22

3.9K

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...

Autophagic Cell Death 01:18

3.5K

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...

Parkinson's Disease: Treatment 01:24

376

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...